lapatinib + gemcitabine + oxaliplatin

This combination therapy consists of lapatinib (GW572016) administered in conjunction with the GEMOX regimen, which comprises gemcitabine and oxaliplatin. Lapatinib is a small molecule dual tyrosine kinase inhibitor that targets both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). Gemcitabine is a nucleoside analog that interferes with DNA synthesis, while oxaliplatin is a platinum-based antineoplastic agent that induces DNA cross-linking. This specific combination was evaluated in the BrUOG-PA-205 Phase I clinical trial sponsored by Brown University, specifically targeting patients with advanced pancreaticobiliary cancers, including pancreatic cancer and biliary tract cancer. Cohort 3 of this trial specifically investigated the safety and efficacy of 1000 mg/day of lapatinib combined with the GEMOX regimen.

Brand names

TykerbTyverbGemzarEloxatin

Other names

cohort 3-Brown University-pancreatic cancer-biliary tract cancercohort3-Brown University-pancreatic cancer-biliary tract cancercohort-3-Brown University-pancreatic cancer-biliary tract cancerlapatinib + GEMOXGW572016 + GEMOXGW572016 + gemcitabine + oxaliplatin